臨床眼科75巻8号

2021年08月発行

連載 今月の話題

加齢黄斑変性診療の最近の動向

著者： 齋藤昌晃¹

所属機関： ¹弘前大学大学院医学研究科眼科学講座

ページ範囲：P.997 - P.1017

　滲出型加齢黄斑変性に対しては抗VEGF療法が主流であるが，長期的なstudyでは網膜色素上皮萎縮と視力低下の関連性が重要視されている。そのため視力を長期的に維持するためには，抗VEGF薬の選択や維持期の投与方法の工夫が必要になってくる。わが国でのこの先の超高齢化社会に向け，さらにはコロナ禍における診療を踏まえ，加齢黄斑変性診療のあり方を考えたい。

参考文献

1）Ferris FL 3rd, Fine SL, Hyman L：Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102：1640-1642, 1984

2）Macular Photocoagulation Study Group：Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109：1220-1231, 1991

3）Gass JD：Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 118：285-298, 1994

4）Treatment of Age-Related Macular Degeneration with Photodynamic Therapy（TAP）Study Group：Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin：one-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol 117：1329-1345, 1999

5）Rosenfeld PJ, Brown DM, Heier JS et al, MARINA Study Group：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355：1419-1431, 2006

6）Brown DM, Kaiser PK, Michels M et al, ANCHOR Study Group：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355：1432-1444, 2006

7）Oshima Y, Ishibashi T, Murata T et al：Prevalence of age related maculopathy in a representative Japanese population：the Hisayama study. Br J Ophthalmol 85：1153-1157, 2001

8）Klein R, Klein BE, Cruickshanks KJ：The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res 18：371-389, 1999

9）Schachat AP, Hyman L, Leske MC et al：Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 113：728-735, 1995

10）Yasuda M, Kiyohara Y, Hata Y et al：Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology 116：2135-2140, 2009

11）Klein R, Klein BE, Knudtson MD et al：Fifteen-year cumulative incidence of age-related macular degeneration：the Beaver Dam Eye Study. Ophthalmology 114：253-262, 2007

12）Wang JJ, Rochtchina E, Lee AJ et al：Ten-year incidence and progression of age-related maculopathy：the blue Mountains Eye Study. Ophthalmology 114：92-98, 2007

13）Leske MC, Wu SY, Hennis A et al, Barbados Eye Studies Group：Nine-year incidence of age-related macular degeneration in the Barbados Eye Studies. Ophthalmology 113：29-35, 2006

14）Dewan A, Liu M, Hartman S et al：HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314：989-992, 2006

15）Yang Z, Camp NJ, Sun H et al：A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314：992-993, 2006

16）Kondo N, Honda S, Ishibashi K et al：LOC387715/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population. Am J Ophthalmol 144：608-612, 2007

17）Nakanishi H, Yamashiro K, Yamada R et al：Joint effect of cigarette smoking, CFH and LOC387715/HTRA1 polymorphisms on polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 51：6183-6187, 2010

18）Kliffen M, Sharma HS, Mooy CM et al：Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81：154-162, 1997

19）Maruko I, Iida T, Saito M et al：Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144：15-22, 2007

20）高橋寛二・石橋達朗・小椋祐一郎・他，厚生労働省網膜脈絡膜・視神経萎縮症調査研究班加齢黄斑変性診断基準作成ワーキンググループ：加齢黄斑変性の分類と診断基準．日眼会誌112：1076-1084，2008

21）Rosenfeld PJ, Brown DM, Heier JS et al, MARINA Study Group：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355：1419-1431, 2006

22）Brown DM, Kaiser PK, Michels M et al, ANCHOR Study Group：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355：1432-1444, 2006

23）Heier JS, Brown DM, Chong V et al, VIEW 1 and VIEW 2 Study Groups：Intravitreal aflibercept（VEGF trap-eye）in wet age-related macular degeneration. Ophthalmology 119：2537-2548, 2012

24）Dugel PU, Koh A, Ogura Y et al, HAWK and HARRIER Study Investigators：HAWK and HARRIER：phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127：72-84, 2020

25）Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group：The neovascular age-related macular degeneration database：multicenter study of 92 976 ranibizumab injections：report 1：visual acuity. Ophthalmology 121：1092-1101, 2014

26）Gass JD：Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 118：285-298, 1994

27）Yannuzzi LA, Sorenson J, Spaide RF et al：Idiopathic polypoidal choroidal vasculopathy（IPCV）. Retina 10：1-8, 1990

28）Yannuzzi LA, Negrão S, Iida T et al：Retinal angiomatous proliferation in age-related macular degeneration. Retina 21：416-434, 2001

29）Spaide RF, Koizumi H, Pozzoni MC et al：Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146：496-500, 2008

30）Fujiwara T, Imamura Y, Margolis R et al：Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes. Am J Ophthalmol 148：445-450, 2009

31）Ikuno Y, Kawaguchi K, Nouchi T et al：Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51：2173-2176, 2010

32）Maruko I, Iida T, Sugano Y et al：Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117：1792-1799, 2010

33）Maruko I, Iida T, Sugano Y et al：Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151：594-603, e1, 2011

34）Yamazaki T, Koizumi H, Yamagishi T et al：Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration：12-month results. Ophthalmology 119：1621-1627, 2012

35）Maruko I, Iida T, Oyamada H et al：Choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy in recurrent polypoidal choroidal vasculopathy. Am J Ophthalmol 156：548-556, 2013

36）Koizumi H, Kano M, Yamamoto A et al：Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related maculardegeneration. Am J Ophthalmol 159：627-633, e1, 2015

37）Koizumi H, Kano M, Yamamoto A et al：Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration：twelve-month results. Ophthalmology 123：617-624, 2016

38）Saito M, Kano M, Itagaki K et al：Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Jpn J Ophthalmol 60：35-41, 2016

39）Spaide RF, Klancnik JM Jr, Cooney MJ：Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol 133：45-50, 2015

40）Inoue M, Balaratnasingam C, Freund KB：Optical coherence tomography angiography of polypoidal choroidal vasculopathy and polypoidal choroidal neovascularization. Retina 35：2265-2274, 2015

41）Takase N, Nozaki M, Kato A et al：Enlargement of foveal avascular zone in diabetic eyes evaluated by en face optical coherence tomography angiography. Retina 35：2377-2383, 2015

42）Ishibazawa A, Nagaoka T, Takahashi A et al：Optical coherence tomography angiography in diabetic retinopathy：a prospective pilot study. Am J Ophthalmol 160：35-44, e1, 2015

43）Spaide RF, Fujimoto JG, Waheed NK et al：Optical coherence tomography angiography. Prog Retin Eye Res 64：1-55, 2018

44）Spaide RF, Ledesma-Gil G：Novel method for image averaging of optical coherence tomography angiography images. Retina 40：2099-2105, 2020

45）Delori FC, Dorey CK, Staurenghi G et al：In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 36：718-729, 1995

46）von Ruckmann A, Fitzke FW, Bird AC：Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol 79：407-412, 1995

47）Piccolino FC, Borgia L, Zinicola E et al：Pre-injection fluorescence in indocyanine green angiography. Ophthalmology 103：1837-1845, 1996

48）Saito M, Itagaki K, Sekiryu T：Fundus autofluorescence of retinal angiomatous proliferation. PLoS One doi：10.1371/journal.pone.0243458, 2020

49）日本ポリープ状脈絡膜血管症研究会：ポリープ状脈絡膜血管症の診断基準．日眼会誌109：417-427，2005

50）Iijima H, Imai M, Gohdo T et al：Optical coherence tomography of idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 127：301-305, 1999

51）Sato T, Kishi S, Watanabe G et al：Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina 27：589-594, 2007

52）Saito M, Iida T, Nagayama D：Cross-sectional and en face optical coherence tomographic features of polypoidal choroidal vasculopathy. Retina 28：459-464, 2008

53）Saito M, Shiragami C, Shiraga F et al：Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 146：935-941, 2008

54）Saito M, Shiragami C, Shiraga F et al：Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 149：472-481, 2010

55）Saito M, Iida T, Kano M：Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 153：504-514, 2012

56）Yannuzzi LA：Degeneration：age-related macular degeneration. In：The Retinal Atlas. 592-602, Saunders, Philadelphia, 2010

57）Bottoni F, Massacesi A, Cigada M et al：Treatment of retinal angiomatous proliferation in age-related macular degeneration：a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 123：1644-1650, 2005

58）Gross NE, Aizman A, Brucker A et al：Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25：713-718, 2005

59）Pang CE, Freund KB：Pachychoroid neovasculopathy. Retina 35：1-9, 2015

60）Miyake M, Ooto S, Yamashiro K et al：Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep doi：10.1038/srep16204, 2015

61）Hata M, Yamashiro K, Ooto S et al：Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 58：292-298, 2017

62）Kato Y, Oguchi Y, Omori T et al：Complement activation products and cytokines in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 61：39, 2020

63）Rofagha S, Bhisitkul RB, Boyer DS et al, SEVEN-UP Study Group：Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON：a multicenter cohort study（SEVEN-UP）. Ophthalmology 120：2292-2299, 2013

64）Ohji M, Takahashi K, Okada AA et al, ALTAIR Investigators：Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration：52- and 96-week findings from ALTAIR：a randomized controlled trial. Adv Ther 37：1173-1187, 2020

65）Chan WM, Lam DS, Lai TY et al：Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy：one-year results of a prospective case series. Ophthalmology 111：1576-1584, 2004

66）Tano Y, Ophthalmic PDT Study Group：Guidelines for PDT in Japan. Ophthalmology 115：585-585, e, 2008

67）Gomi F, Ohji M, Sayanagi K et al：One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115：141-146, 2008

68）Kurashige Y, Otani A, Sasahara M et al：Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146：513-519, 2008

69）Saito M, Iida T, Nagayama D：Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy：comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 92：1642-1647, 2008

70）Koh A, Lai TYY, Takahashi K et al, EVEREST Ⅱ study group：Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy：a randomized clinical trial. JAMA Ophthalmol 135：1206-1213, 2017

71）Lee WK, Iida T, Ogura Y et al, PLANET Investigators：Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET Study：a randomized clinical trial. JAMA Ophthalmol 136：786-793, 2018

72）髙橋寛二・小椋祐一郎・石橋達郎・他：加齢黄斑変性の治療指針．日眼会誌116：1150-1155，2012

73）McBain VA, Kumari R, Townend J et al：Geographic atrophy in retinal angiomatous proliferation. Retina 31：1043-1052, 2011

74）Cho HJ, Yoo SG, Kim HS et al：Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159：285-292, 2015

75）Hata M, Yamashiro K, Oishi A et al：Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor injections for retinal angiomatous proliferation. Retina 37：2069-2077, 2017

76）Saito M, Iida T, Kano M et al：Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Jpn J Ophthalmol 60：42-50, 2016

77）Gillies MC, Hunyor AP, Arnold JJ et al：Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration：a randomized clinical trial. JAMA Ophthalmol 137：372-379, 2019

78）Gillies MC, Hunyor AP, Arnold JJ et al：Macular atrophy in neovascular age-related macular degeneration：a randomized clinical trial comparing ranibizumab and aflibercept（RIVAL Study）. Ophthalmology 127：198-210, 2020

79）Jung BJ, Kim JY, Lee JH et al：Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep doi：10.1038/s41598-019-38504-y, 2019

80）Matsumoto H, Mukai R, Kikuchi Y et al：One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64：203-209, 2020

81）Freund KB, Laud K, Lima LH et al：Acquired vitelliform lesions：correlation of clinical findings and multiple imaging analyses. Retina 31：13-25, 2011

82）Saito M, Iida T, Freund KB et al：Clinical findings of acquired vitelliform lesions associated with retinal pigment epithelial detachments. Am J Ophthalmol 157：355-365, 2014

83）Baumal CR, Spaide RF, Vajzovic L et al：Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. ophthalmology 127：1345-1359, 2020

84）Hikichi T：Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn J Ophthalmol 65：208-214, 2021

85）Kataoka K, Horiguchi E, Kawano K et al：Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy. Jpn J Ophthalmol 65：199-207, 2021

86）Saito M, Barbazetto IA, Spaide RF：Intravitreal cellular infiltrate imaged as punctate spots by spectral domain optical coherence tomography in eyes with posterior segment inflammatory disease. Retina 33：559-565, 2013

87）髙橋寛二・白神史雄・石田　晋・他，厚生労働省網膜脈絡膜・視神経萎縮症調査研究班萎縮型加齢黄斑変性診療ガイドライン作成ワーキンググループ：萎縮型加齢黄斑変性の診断基準．日眼会誌119：671-677，2015

88）Age-Related Eye Disease Study Research Group：A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss：AREDS report no. 8. Arch Ophthalmol 119：1417-1436, 2001

89）Takahashi H, Tampo H, Arai Y et al：Applying artificial intelligence to disease staging：Deep learning for improved staging of diabetic retinopathy. PLoS One doi：10.1371/journal.pone.0179790, 2017

90）Mandai M, Watanabe A, Kurimoto Y et al：Autologous induced stem-cell-derived retinal cells for macular degeneration. N Engl J Med 376：1038-1046, 2017

91）Felfeli T, Mandelcorn ED：Assessment of simulated respiratory droplet spread during an ophthalmologic slitlamp examination. JAMA Ophthalmol 138：1099-1101, 2020

92）Spaide RF, Jaffe GJ, Sarraf D et al：Consensus Nomenclature for reporting neovascular age-related macular degeneration data：consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127：616-636, 2020